Haemonetics (NYSE:HAE) Posts Earnings Results, Beats Expectations By $0.06 EPS

Haemonetics (NYSE:HAE) announced its quarterly earnings results on Thursday. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06, FiscalAI reports. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The business had revenue of $339.38 million for the quarter, compared to the consensus estimate of $327.86 million. During the same quarter last year, the business posted $1.10 EPS. The business’s revenue was up 5.5% on a year-over-year basis.

Here are the key takeaways from Haemonetics’ conference call:

• Haemonetics raised fiscal 2027 guidance, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, following first-quarter revenue growth of 6% and adjusted EPS growth of 4% to $1.14.
• Plasma revenue increased 8% organically, supported by double-digit disposable growth, share gains, strong collection volumes, and the early rollout of Persona PLUS, which is delivering more than 5% yield improvements for early adopters.
• Interventional technologies returned to growth, led by low-double-digit vascular closure growth. The VASCADE MVP XL indication expansion, new clinical evidence, and stronger sales execution are supporting account wins and increased utilization in PFA and other large-bore procedures.
• Cash generation was strong, with operating cash flow tripling year over year to $52 million and trailing-12-month free-cash-flow conversion reaching 106% of adjusted net income. The company used cash to repay $100 million of revolver debt and retains flexibility for growth investments and opportunistic share repurchases.
• External cost pressures remain a headwind, including tariffs, transportation and oil-related costs, material inflation, and higher personnel expenses. Slower cell-salvage capital upgrades and weakness in OEM and esophageal-cooling businesses also weighed on parts of MedSurg and interventional technologies.

Haemonetics Price Performance

Haemonetics stock traded up $2.48 during trading hours on Friday, hitting $87.50. 657,064 shares of the company traded hands, compared to its average volume of 737,142. Haemonetics has a 1-year low of $47.31 and a 1-year high of $88.58. The firm has a market cap of $3.98 billion, a P/E ratio of 42.89, a P/E/G ratio of 1.71 and a beta of 0.52. The firm’s 50-day simple moving average is $76.98 and its two-hundred day simple moving average is $66.52. The company has a quick ratio of 1.87, a current ratio of 3.08 and a debt-to-equity ratio of 1.40.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Analyst Ratings Changes

Several brokerages have weighed in on HAE. Barrington Research set a $95.00 target price on Haemonetics in a research report on Friday. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Raymond James Financial reiterated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a research report on Friday. Mizuho boosted their target price on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Finally, BTIG Research upped their target price on shares of Haemonetics from $84.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $90.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. acquired a new stake in Haemonetics in the fourth quarter worth approximately $26,000. EverSource Wealth Advisors LLC increased its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of Haemonetics in the 4th quarter worth $34,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Haemonetics by 20,925.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 837 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Haemonetics by 110.9% in the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 306 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.